Funding for this research was provided by:
U.S. Food and Drug Administration (U18 FD005320)
Received: 8 June 2017
Accepted: 20 February 2018
First Online: 27 February 2018
: SE has over 20 years of experience in translation, cultural adaptation, and linguistic validation of PRO measures and served as co-chair of the International Society for Quality of Life (ISOQOL) Translation and Cultural Adaptation Special Interest Group from 2013 to 2017. She has also co-authored several publications on translation and linguistic validation methodology.
: Not applicable as this manuscript does not report or involve the use of any animal or human data or tissue.
: Not applicable
: SE is an employee of the Critical Path Institute and has no competing interests.SP is an employee and shareholder of Pfizer and has no competing interests.SM is an employee of the Critical Path Institute and has no competing interests.PB was an employee and shareholder of GlaxoSmithKline at the time the work described in the manuscript was conducted. She is currently an employee and shareholder of Janssen and has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.